Antisense Inhibition of Angiotensinogen With IONIS-AGT-L(Rx): Results of Phase 1 and Phase 2 Studies

Targeting angiotensinogen (AGT) may provide a novel approach to more optimally inhibit the renin-angiotensin-aldosterone system pathway. Double-blind, placebo-controlled clinical trials were performed in subjects with hypertension as monotherapy or as an add-on to angiotensin-converting enzyme inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Erin S., Tami, Yvonne, Hu, Kuolung, Brambatti, Michela, Mullick, Adam E., Geary, Richard S., Bakris, George L., Tsimikas, Sotirios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246029/
https://www.ncbi.nlm.nih.gov/pubmed/34222719
http://dx.doi.org/10.1016/j.jacbts.2021.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246029/
https://www.ncbi.nlm.nih.gov/pubmed/34222719
http://dx.doi.org/10.1016/j.jacbts.2021.04.004

Ejemplares similares